No results were found for the filter!
SARS-CoV-2-IN-49
Item number: TGM-T79227-50mg
Description: SARS-CoV-2-IN-49 acts as an irreversible covalent inhibitor targeting the main protease of SARS-CoV-2 [1]. Target: SARS-CoV
| MW: | 535.61 D |
Please request pricing for this article.
SARS-CoV-2-IN-50
Item number: TGM-T79228-50mg
Description: SARS-CoV-2-IN-50 (Compound X77C) is a potent inhibitor of the SARS-CoV-2 main protease (M^pro), demonstrating high affinity for the enzyme's catalytic site [1]. Target: SARS-CoV
| MW: | 493.53 D |
Please request pricing for this article.
ETAP
Item number: TGM-T79229-100mg
Description: ETAP, a dual inhibitor of both monoamine oxidase A (MAO-A) and monoamine oxidase B (MAO-B), exhibits antidepressant-like effects and is utilized in the research of major depressive disorder [1]. Target: Monoamine Oxidase
| CAS | 2575731-47-2 |
| MW: | 291.35 D |
From 1,440.00€
*
JET-209
Item number: TGM-T79230-1mg
Description: JET-209 is a potent proteolysis-targeting chimera (PROTAC) that effectively degrades CBP/p300, exhibiting half-maximal degradation concentration (DC50) values of 0.05 nM for CBP and 0.2 nM for p300. The compound comprises lenalidomide (the cereblon ligand), a connecting linker, and GNE-207 (the...
| MW: | 821.92 D |
729.00€
*
MARK4 inhibitor 2
Item number: TGM-T79232-50mg
Description: MARK4 Inhibitor 2 is a potent inhibitor of Microtubule Affinity-Regulating Kinase 4 (MARK4), exhibiting a Km of 6.3×107 and an IC50 of 0.82 µM. It effectively inhibits the growth of human cells, thereby offering potential for use in cancer research [1]. Target: AMPK
| MW: | 542.63 D |
Please request pricing for this article.
RdRP-IN-6
Item number: TGM-T79233-50mg
Description: RdRP-IN-6 (compound 27) is an RNA-dependent RNA polymerase (RdRp) inhibitor with an IC90 value of 14.1 µM, and it shows potential applications in antiviral and anticancer research [1]. Target: DNA/RNA Synthesis
| MW: | 871.16 D |
Please request pricing for this article.
RdRP-IN-7
Item number: TGM-T79234-50mg
Description: RdRP-IN-7, a RNA-dependent RNA polymerase (RdRp) inhibitor, demonstrates efficacy against SARS-CoV-2 infection with an inhibitory concentration (IC50) of 8.2 µM and (IC90) of 14.1 µM, alongside a cytotoxic concentration (CC90) of 79.1 µM, rendering it suitable for antiviral research [1]. Target: SARS-CoV
| MW: | 559.85 D |
Please request pricing for this article.
JAK-IN-30
Item number: TGM-T79235-10mg
Description: JAK-IN-30 (compound 31) is a water-soluble Janus kinase (JAK) inhibitor with IC50 values of 2 nM for JAK2, 15 nM for JAK1, 18 nM for JAK3, and 2 nM for TYK2, identified for its research potential in treating dry eye disease (DED) [1]. Target: JAK
| Application: | JAK2 inhibitor |
| CAS | 2891469-99-9 |
| MW: | 398.53 D |
From 168.00€
*
7OQL
Item number: TGM-T79236-50mg
Description: Compound 54 (7OQL) is a selective METTL3 inhibitor with an IC50 value of 0.054 µM, showing promise for cancer research applications [1]. Target: Others
| MW: | 590.8 D |
Please request pricing for this article.
alpha-Glucosidase-IN-27
Item number: TGM-T79237-50mg
Description: alpha-Glucosidase-IN-27 (compound 8l), an alpha-glucosidase inhibitor with an IC50 of 25.78 µM, demonstrates potential for type 2 diabetes (D2M) research [1]. Target: Glucosidase
| MW: | 436.48 D |
Please request pricing for this article.
SDH-IN-3
Item number: TGM-T79238-50mg
Description: SDH-IN-3 is a succinate dehydrogenase (SDH) inhibitor with potent antifungal activity, demonstrating an inhibition concentration (IC50) of 7.2 µg/mL and an effective concentration (EC50) of 1.9 µg/mL against Nigrospora oryzae, making it valuable for anti-infection research [1]. Target: Antibiotic
| CAS | 2805297-11-2 |
| MW: | 319.33 D |
Please request pricing for this article.
PCSK9-IN-19
Item number: TGM-T79239-50mg
Description: PCSK9-IN-19 (Compound 1), a PCSK9 inhibitor, is utilized in researching the treatment of high LDL-cholesterol levels and the prevention of coronary artery disease [1]. Target: Others
| MW: | 1647.37 D |
Please request pricing for this article.